HDAC inhibitors target metabolism in brain tumors.
HDAC Inhibitors Reverse the Warburg Effect and Elicit Metabolic Vulnerabilities in Model Systems of Glioblastoma
This study is looking at how certain medications can change the way glioblastoma cells use energy, which might make them more sensitive to treatments and help patients with this type of brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11064855 on NIH RePORTER |
What this research studies
This research investigates how HDAC inhibitors can reverse the Warburg effect, a metabolic process that glioblastoma cells exploit to survive. By using specific compounds like panobinostat and vorinostat, the study aims to reprogram the metabolism of glioblastoma cells, leading to reduced glycolysis and increased oxidative phosphorylation. This approach could enhance the effectiveness of treatments by making cancer cells more vulnerable to apoptosis, or programmed cell death. Patients may benefit from new therapeutic strategies that specifically target the metabolic vulnerabilities of their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma multiforme who are seeking novel treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results with similar metabolic targeting approaches in cancer treatment, indicating potential for success in this area.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Siegelin, Markus D — Columbia University Health Sciences
- Study coordinator: Siegelin, Markus D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.